Pexiganan matched ofloxacin in pooled data but missed approval twice

What is pexiganan?

Pexiganan is a synthetic peptide analog of the magainin family, the antimicrobial peptides first isolated from frog skin. Pexiganan disrupts bacterial cell membranes instead of blocking a single enzyme or ribosomal target the way conventional antibiotics do. That difference is the basis for the standard argument that membrane-disrupting peptides resist the point mutations that drive antibiotic resistance.

As a topical cream, pexiganan is active against most of the organisms typically isolated from diabetic foot infections ^[4]. That in vitro and spectrum-of-activity record is not in dispute. The open question is whether that activity produces a clinical benefit large enough, and consistent enough, to clear a regulatory bar.

How did pexiganan perform against oral ofloxacin?

Pexiganan cream matched oral ofloxacin in pooled data from two double-blind, multicenter trials, studies 303 and 304, in patients with mildly infected diabetic foot ulcers ^[1]. The full results were published in 2008, years after the trials ran ^[1].

Across 835 randomized patients, the combined analysis showed:

• Clinical improvement: 85%-90% in both arms ^[1].
• Microbiological eradication: 42%-47% ^[1].
• Wound healing: similar rates in both arms ^[1].
• Worsening cellulitis: 2%-4% of patients ^[1].

For a topical peptide against a systemic fluoroquinolone, that is a respectable non-inferiority result.

Why was pexiganan rejected after its first Phase 3 program?

Study 303 alone failed to demonstrate equivalence; only study 304 and the pooled analysis cleared the pre-specified margin ^[1]. A regulator looking at one trial that missed, and a combined analysis that worked only once the data were merged, has a legitimate design objection that says nothing about whether the peptide kills bacteria.

A 2006 systematic review of antimicrobial treatments for diabetic foot ulcers reached the same cautious conclusion from the other direction. The review found that pexiganan cream "may be as effective" as oral ofloxacin, but judged the evidence for every antimicrobial agent in this population, topical or systemic, too weak and too heterogeneous to recommend a particular one ^[2]. The first program was a regulatory-design and evidence-strength failure, not a demonstration that the mechanism fails.

What happened in pexiganan's second Phase 3 program?

The second program, run roughly two decades later, tested pexiganan cream against a vehicle, inactive cream plus standard wound care, and missed. That design is the more direct test of whether the peptide does anything beyond debridement and dressing. Its specific results and statistics are not reported in the studies cited below.

One confound makes any single vehicle-controlled miss hard to interpret. Reviews of topical antimicrobial treatment for diabetic foot ulcers describe small, heterogeneous trials and considerable uncertainty about whether any topical agent, active or not, reliably separates from standard wound care ^[3]. Standard care itself, meaning debridement, offloading and glycemic management, does meaningful work in these ulcers. That raises the bar any add-on cream has to clear and shrinks the visible gap between an active peptide and an inactive one.

Is the problem pexiganan's delivery or its killing mechanism?

The evidence points to delivery. The most useful comparison is a newer peptide in the same structural class. A 2026 multicenter, double-blind, placebo-controlled trial of PL-5 (peceleganan) spray in mildly to moderately infected diabetic foot ulcers found ^[5]:

• Clinical response: significantly higher with the active peptide.
• Drug-resistant organisms: a significantly higher clearance rate, 71.43% versus 50%.
• Overall microbiological eradication: no significant difference at the end of treatment (57.89% versus 33.33%) or one week later (64.71% versus 40.00%).

PL-5 produced the same split decision with a different molecule, a comparable membrane-disrupting mechanism and the same indication, nearly a decade after pexiganan's second program. That pattern suggests the ceiling for this class in this indication is real and reproducible across molecules, and that the sticking point is getting a topical peptide to sterilize tissue consistently, not the membrane-disruption concept itself.

Diabetic foot wounds carry their own barriers. Biofilm and impaired local perfusion are recognized barriers to any local antimicrobial reaching an effective concentration at the site of infection ^[4]. That is a delivery and pharmacokinetic problem, not evidence that the peptide's killing mechanism is inert.

What is still unknown about pexiganan?

The open questions are the ones that would settle the delivery hypothesis:

• Tissue exposure. None of the studies cited below measures pexiganan's tissue penetration, local degradation rate or effective concentration at the ulcer bed in either Phase 3 program, so the delivery-failure explanation is plausible, not proven.
• Modern comparison. No head-to-head trial compares pexiganan with a newer peptide such as PL-5.
• Comparator response. The placebo and standard-care response in pexiganan's second program is not documented here, only the general pattern that diabetic foot ulcer trials produce unusually active comparator arms ^[3]⁠^[2].

Pexiganan's two failures are evidentiary opposites: a design-flawed non-inferiority program in 1999 and a cleaner but unexplained vehicle-controlled miss later. Neither one, alone or combined, falsifies membrane disruption as a mechanism. The broader antimicrobial and wound-healing peptide evidence shows the same gap between laboratory activity and clinical benefit.